Rhumbline Advisers Spero Therapeutics, Inc. Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$1.42 - $1.95 $650 - $893	458 New	458 $0
Q2 2022 Aug 11, 2022	SELL	$0.74 - $7.44 $18,307 - $184,065	-24,740 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$7.87 - $15.15 $43,119 - $83,006	5,479 Added 28.45%	24,740 $215,000
Q4 2021 Feb 10, 2022	SELL	$13.09 - $18.77 $4,306 - $6,175	-329 Reduced 1.68%	19,261 $308,000
Q3 2021 Nov 12, 2021	BUY	$13.03 - $19.51 $13,355 - $19,997	1,025 Added 5.52%	19,590 $361,000
Q2 2021 Aug 05, 2021	BUY	$12.22 - $15.79 $1,539 - $1,989	126 Added 0.68%	18,565 $259,000
Q1 2021 May 06, 2021	SELL	$13.23 - $21.48 $10,279 - $16,689	-777 Reduced 4.04%	18,439 $271,000
Q4 2020 Feb 10, 2021	BUY	$11.65 - $22.07 $53,217 - $100,815	4,568 Added 31.19%	19,216 $373,000
Q3 2020 Nov 12, 2020	SELL	$8.96 - $14.12 $29,397 - $46,327	-3,281 Reduced 18.3%	14,648 $163,000
Q2 2020 Aug 13, 2020	BUY	$7.27 - $14.18 $10,992 - $21,440	1,512 Added 9.21%	17,929 $243,000
Q1 2020 May 06, 2020	BUY	$5.27 - $10.41 $5,428 - $10,722	1,030 Added 6.69%	16,417 $133,000
Q4 2019 Feb 05, 2020	BUY	$9.46 - $12.16 $3,263 - $4,195	345 Added 2.29%	15,387 $148,000
Q3 2019 Oct 23, 2019	BUY	$9.01 - $12.55 $13,343 - $18,586	1,481 Added 10.92%	15,042 $159,000
Q2 2019 Aug 14, 2019	BUY	$10.25 - $14.36 $27,347 - $38,312	2,668 Added 24.49%	13,561 $156,000
Q1 2019 May 01, 2019	BUY	$6.26 - $13.31 $5,527 - $11,752	883 Added 8.82%	10,893 $140,000
Q4 2018 Jan 31, 2019	BUY	$5.69 - $11.28 $56,956 - $112,912	10,010 New	10,010 $62,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $41.4M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.